Cheskin LJ, Hill C, Adam A, Fayad L, Dunlap M, Badurdeen D, Koller K, Bunyard L, Frutchey R, Al-Grain H, Kahan S, Hedjoudje A,
Khashab MA, Kalloo AN, Kumbhari V.
Gastrointest Endosc. 2019
BACKGROUND AND AIMS:
Endoscopic sleeve gastroplasty (ESG) is a safe and effective minimally invasive bariatric procedure. This study compared
weight loss in patients undergoing ESG with that of matched patients undergoing high-intensity diet and lifestyle therapy
In this case-matched study, patients were matched 2/3:1 (HIDLT/ESG) by age, sex, and body mass index (BMI). One hundred
five patients (30 men) who underwent ESG + low-intensity diet and lifestyle therapy (LIDLT) between 2016 and 2018 were
compared with 281 patients (92 men) who underwent HIDLT at the Johns Hopkins Medical Institutions from 2013 to 2014.
Weight was evaluated 1, 3, 6, and 12 months after beginning HIDLT or post-ESG to determine the mean percent total body
weight loss (%TBWL).
Mean age across both cohorts was 48.0 ± 12.1, and baseline BMI was 40.0 ± 7.7 kg/m2. In multivariable analysis controlling
for age, sex, and baseline BMI, the mean %TBWL at 1, 3, 6, and 12 months was significantly higher in patients undergoing
ESG than matched patients undergoing HIDLT. Specifically, at 3 months, the mean %TBWL in the ESG cohort was 14.0%
compared with 11.3% in the HIDLT cohort (P <.011), and at 12 months the mean %TBWL in the ESG cohort was 20.6% versus
14.3% in the HIDLT cohort (P < .001). ESG patients with baseline BMI ≤40 kg/m2 continued to show significantly greater
%TBWL than those of the same BMI group in the HIDLT group at 1, 3, 6, and 12 months after intervention (3 months,
coefficient = 3.43 [P < .001]; 12 months, coefficient = 8.14 [P < .001]).
Through 12 months of follow-up, patients who underwent ESG achieved significantly greater weight loss than patients
enrolled in HIDLT. ESG appears to be a valuable alternative for patients who experience difficulty complying with HIDLT.